Five updates:
1. Bioventus launched its initial public offering: 7.35 million shares of its Class A common stock priced between $16 and $18 per share.
2. Larry Chen was appointed as managing director of the company’s China and Asian Pacific region.
3. Bioventus has acquired rehabilitation solutions company Bioness for $45 million upfront consideration, with up to $65 million contingent consideration.
4. In the first quarter of 2021, Bioventus saw year-over-year net income growth, roping in $24.5 million.
5. Bioventus has launched a new allograft substitute product, Osteoamp Select Flowable. The allograft is optimal for minimally invasive surgeries and can be used in a various spine and foot and ankle procedures.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
